Uncertain BENEFIT of early interferon beta-1b treatment

The Lancet Neurology

Volumn 8, Issue 11, 2009, Pages 970-971

  Pittock, Sean J ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; BETA INTERFERON; INTERFERON BETA-1B;

DRUG COST; FOLLOW UP; HUMAN; LETTER; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; CLINICAL TRIAL; DEMYELINATING DISEASE; DISABILITY; DISEASE COURSE; NOTE; RISK ASSESSMENT; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DEMYELINATING DISEASES; DISABILITY EVALUATION; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 70449711297     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70258-3     Document Type: Letter

References (10)

1. Jacobs L.D., Beck R.W., Simon J.H., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343 (2000) 898-904
2. Comi G., Filippi M., Barkhof F., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357 (2001) 1576-1582
3. Kappos L., Polman C.H., Freedman M.S., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67 (2006) 1242-1249
4. Pittock S.J. Interferon beta in multiple sclerosis: how much BENEFIT?. Lancet 370 (2007) 363-364
5. Siva A. Immunotherapy for clinically isolated syndrome? Not necessarily. Nat Clin Pract Neurol 4 (2008) 236-237
6. Kappos L., Freedman M.S., Polman C.H., et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370 (2007) 389-397
7. Kappos L., Freedman M.S., Polman C.H., et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 10.1016/S1474-4422(09)70237-6 published online Sept 11.
8. Kinkel R.P., Tanner J.P., Simon J., O'Connor P.W., Kollman C., and for the Champions Study Group. CHAMPIONS extension study: 10 year follow-up after a clinically isolated syndrome (CIS) in high risk patients. Neurology 72 (2009) A315
9. Miller D., Barkhof F., Montalban X., Thompson A., and Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 4 (2005) 281-288
10. Comi G. Clinically isolated syndrome: the rationale for early treatment. Nat Clin Pract Neurol 4 (2008) 234-235